Menu Search
Equities

CStone Pharmaceuticals

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PH4:MUN

CStone Pharmaceuticals

Actions
  • Price (EUR)0.565
  • Today's Change0.000 / 0.00%
  • Shares traded2.00k
  • 1 Year change+84.64%
  • Beta1.1789
Data delayed at least 15 minutes, as of Feb 10 2026 07:13 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.

  • Revenue in HKD (TTM)228.01m
  • Net income in HKD-424.61m
  • Incorporated2015
  • Employees93.00
  • Location
    CStone Pharmaceuticals1000 Zhangheng Road Bldg 25Pudong New DistrictSUZHOU 200072ChinaCHN
  • Phone+86 51 287186550
  • Websitehttps://www.cstonepharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.